inixaciclib   Click here for help

GtoPdb Ligand ID: 12078

Synonyms: compound 442 [WO2019161224A1] | example 50 [WO2019161224A1]
Compound class: Synthetic organic
Comment: We obtained the chemical structure for inixaciclib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a cyclin-dependent kinase inhibitor and antineoplastic. This Chemical structure mapped to PubChem CID 139390026, and then to compound 442 in GiraFpharma's patent WO2019161224A1 which claims compounds as CDK4 or CDK6 inhibitors for use as anticancer drugs [1]. We have been unable to map inixaciclib to a company research code.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 66.41
Molecular weight 480.24
XLogP 4.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCC(CC1)c1ccc(nc1)Nc1ncc(c(n1)c1cc(F)c2c(c1)N(CCO2)C(C)C)F
Isomeric SMILES Fc1c(nc(nc1)Nc1ncc(cc1)C1CCN(CC1)C)c1cc(c2c(N(CCO2)C(C)C)c1)F
InChI InChI=1S/C26H30F2N6O/c1-16(2)34-10-11-35-25-20(27)12-19(13-22(25)34)24-21(28)15-30-26(32-24)31-23-5-4-18(14-29-23)17-6-8-33(3)9-7-17/h4-5,12-17H,6-11H2,1-3H3,(H,29,30,31,32)
InChI Key YZSCPLGKKMSBMV-UHFFFAOYSA-N
References
1. Pham SM, Chakravarty S, Kanlanala J, Pujala B, Shete A, Bhatt B, Agarwal AK, Soni S, Chen J. (2019)
Heterocyclic compounds as kinase inhibitors.
Patent number: WO2019161224A1. Assignee: GiraFpharma LLC. Priority date: 15/02/2018. Publication date: 22/08/2019.